🔗 Share this article

As America proceeds with unprecedented changes to its vaccine schedules, an unexpected name appears in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by casting doubt on Covid shots in the global health crisis and has zeroed in on potential fatalities following COVID-19 vaccination in her short position at the FDA.

Planned Overhauls to Childhood Immunization Program

Agency leaders were set to unveil major changes to the pediatric immunization program earlier this month, bringing the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US at odds with much of the world with insufficient data for improved outcomes. This reveal has been postponed until the new year.

Instead of Vinay Prasad, Høeg is scheduled to speak at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth individual to lead the office this year.

A Shift at the Regulatory Body

This interim role could signify a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing some childhood shot schedules in the US to become more similar to Denmark's approach, a nation with universal health coverage and a number of inhabitants about the size of Wisconsin’s.

So far statements, she has persisted in emphasizing on vaccines – typically the domain of Prasad, director of the FDA’s vaccine center – as opposed to drug regulation.

Questions Over Background

The appointee has little discernible background in medication creation, regulation or administrative roles, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a large organization. She lacks background in pharmaceutical oversight.”

Past directors of the center would “understand legal statutes and the science of drug development”, noted Janet Woodcock. “Objectively, she lacks the sort of resume that former directors who ran the center have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner emphasized.

“The public just focuses on the new drug program, but the generic program clears numerous off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and more, and all of those must be managed,” Woodcock noted. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial management element to the role, which manages in excess of 5,000 employees. “It’s a huge management job, if you execute it properly,” she concluded.

Agency Reaction and Controversial Initiatives

Regarding concerns about Dr. Høeg's credentials and whether this appointment represents increased cooperation among agency officials on vaccines, a spokesperson responded that the “questions are based on inaccurate presumptions”.

“This background aligns with the responsibilities of her role,” the representative stated, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's controversial fast-track approval initiative, a contentious rapid drug-approval program that allegedly concerned her predecessors. “How are these therapies being selected for this fast-track system? Who makes the choices?” Howard questioned. “There’s a lot of confidentiality occurring at the FDA right now.”

In general, he stated, “the FDA appears to be shifting towards less stringent regulations of all drugs, with the exception of vaccines.”

Documented Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if troubling, track record, some experts have noted. She released a study using unverified public submissions to determine the rate of heart inflammation after Covid immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have modified findings to imply Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the incoming government included revising guidelines for new vaccines and ending “unnecessary” immunizations, she stated post-election on a audio program. At the agency, Høeg has according to sources suggested preventing teenage boys from receiving Covid vaccines.

“She’s an all-around dogmatist who begins with her conclusions and reverse-engineers to retrofit the science in a extremely disingenuous, fraudulent manner,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with fellow dissenters, {like|